Evaxion A (EVAX) Income towards Parent Company (2020 - 2026)
Evaxion A's (EVAX) quarterly Income towards Parent Company came in at -$3.6 million in Q1 2026, down 129.68% YoY from $12.2 million in Q1 2025, and up 38.68% on a QoQ basis from -$5.9 million in Q4 2025.
Evaxion A (EVAX) Income towards Parent Company (2020 - 2026) Analysis & Trends
Evaxion A (EVAX) has 7 years of Income towards Parent Company data on file, last reported at -$3.6 million in Q1 2026.
- Quarterly Income towards Parent Company fell 129.68% year-over-year to -$3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.8 million (up 26.85% YoY) and the FY2025 annual result came in at -$7.7 million, up 27.07% from the prior year.
- Income towards Parent Company advanced to -$3.6 million in Q1 2026, from -$5.9 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $5.8 million in Q1 2022 to a low of -$6.9 million in Q4 2022.
- A 5-year average of -$3.3 million and a median of -$4.8 million in 2022 frame the typical range for Income towards Parent Company.
- The widest YoY moves for Income towards Parent Company: up 338.66% in 2025, down 232.33% in 2025.
- Tracing EVAX's Income towards Parent Company over 5 years: stood at -$6.9 million in 2022, then soared by 34.18% to -$4.5 million in 2023, then increased by 19.77% to -$3.6 million in 2024, then sank by 63.08% to -$5.9 million in 2025, then soared by 38.68% to -$3.6 million in 2026.
- The last three Income towards Parent Company figures came in at -$3.6 million (Q1 2026), -$5.9 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Evaxion A | 27.61 Mn | 27.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.63 Mn |
| Dec 31, 2025 | -5.92 Mn |
| Sep 30, 2025 | 4.62 Mn |
| Jun 30, 2025 | -4.83 Mn |
| Mar 31, 2025 | -1.58 Mn |
| Dec 31, 2024 | -3.63 Mn |
| Sep 30, 2024 | -1.94 Mn |
| Jun 30, 2024 | -6.20 Mn |
| Mar 31, 2024 | 1.19 Mn |
| Dec 31, 2023 | -4.52 Mn |
| Sep 30, 2023 | -5.68 Mn |
| Jun 30, 2023 | -5.68 Mn |
| Mar 31, 2023 | -6.24 Mn |
| Dec 31, 2022 | -6.87 Mn |
| Sep 30, 2022 | -5.74 Mn |
| Jun 30, 2022 | -4.77 Mn |
| Mar 31, 2022 | 5.79 Mn |
| Dec 31, 2021 | -8.37 Mn |
| Sep 30, 2021 | 16.16 Mn |
| Jun 30, 2021 | -10.91 Mn |